StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)

Close on Nov 18, 2026Market cap $6.09BP/E –Yield –

Arrowhead Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Arrowhead Pharmaceuticals's pe ratio was 48.0× on Apr 30, 2026, against 87.1× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202648.0×−382.7
2020Jul 31, 2020430.7×+338.8
2019Dec 31, 201991.9×–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?